Shannon McCue
Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. RMD Open 2022; 8
01.07.2022Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
01.07.2022RMD Open 2022; 8
Hatemi Gülen, Mahr Alfred, Takeno Mitsuhiro, Kim Doyoung, Melikoğlu Melike, Cheng Sue, McCue Shannon, Paris Maria, Chen Mindy, Yazici Yusuf
Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial
Hatemi G, Chen M, Paris M, McCue S, Cheng S, Melikoğlu M, Direskeneli H, Saadoun D, Kim D, Takeno M, Mahr A, Yazici Y. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. Clin Exp Rheumatol 2021; 39 Suppl 132:80-87.
06.10.2021Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial
06.10.2021Clin Exp Rheumatol 2021; 39 Suppl 132:80-87
Hatemi Gülen, Chen Mindy, Paris Maria, McCue Shannon, Cheng Sue, Melikoğlu Melike, Direskeneli Haner, Saadoun David, Kim Do Young, Takeno Mitsuhiro, Mahr Alfred, Yazici Yusuf